CSF samples were obtained by LP following a standard procedure, centrifuged in case of blood contamination, divided into aliquots, and stored in polypropylene tubes at − 80 °C until analysis. CSF total tau (t-tau) and p-tau were measured by chemiluminescent enzyme immunoassays on the automated Lumipulse G600II platform (Fujirebio), as described [28 (link)]. The inter-assay coefficients of variation (CVs) were < 8% for both biomarkers. We used commercially available ELISA kits to measure CSF NfL and 14–3-3 gamma isoform, as described [14 (link), 29 (link)]. SNAP-25 concentrations were determined by running the commercially available SNAP-25 Advantage Kit (Quanterix) on the SIMOA SR-X platform (Quanterix). Ng concentrations were assessed with ELISA technology using the Human Neurogranin (Trunc P75) ELISA Kit (EUROIMMUN). The intra-assay and the inter-assay CVs were < 8% and < 15%, respectively, for all four biomarkers. As previously reported, all CSF samples from patients without autopsy examination, classified as probable sCJD or np-RPD, were tested by second-generation prion CSF RT-QuIC [9 (link)].
Free full text: Click here